Abclon Inc.
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
May 2034
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 25, 2027The maintenance fee for Antibody or antigen-binding fragment thereof that specifically recognizes B cell malignancies, chimeric antigen receptor comprising same, and uses thereof (US 11,708,409) comes due Jan 25, 2027. Unpaid by Jul 26, 2027, it lapses early.
- 1 fee due May 5, 2027The maintenance fee for Antibodies against vascular endothelial growth factor receptor 2 (VEGFR2), encoding nucleic acid molecules and methods for treating an angiogenesis-related disease (US 10,465,008) comes due May 5, 2027. Unpaid by Nov 5, 2027, it lapses early.
- 2 fees due Oct 2 to 28, 2027 · next Oct 2
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,174,116 | Antibody specifically binding to HER2 In force · From the USPTO record | In force | From the USPTO record | |
| US 10,633,423 | IL-6-binding polypeptide complex In force · From the USPTO record | In force | From the USPTO record | |
| US 10,465,008 | Antibodies against vascular endothelial growth factor receptor 2 (VEGFR2), encoding nucleic acid molecules and methods for treating an angiogenesis-related disease In force · From the USPTO record | In force | From the USPTO record | |
| US 11,248,059 | Antibody having improved stability and specifically binding to HER2 In force · From the USPTO record | In force | From the USPTO record | |
| US 12,090,171 | Antibody or Antigen Binding Fragment Thereof for Specifically Recognizing B Cell Malignancy, Chimeric Antigen Receptor Comprising Same and Use Thereof In force · High confidence | In force | High confidence | |
| US 11,708,409 | Antibody or antigen-binding fragment thereof that specifically recognizes B cell malignancies, chimeric antigen receptor comprising same, and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 11,945,878 | Switch molecule and switchable chimeric antigen receptor In force · From the USPTO record | In force | From the USPTO record | |
| US 11,534,462 | Antibody Or Antigen Binding Fragment Thereof For Specifically Recognizing B Cell Malignancy, Chimeric Antigen Receptor Comprising Same And Use Thereof In force · High confidence | In force | High confidence | |
| US 12,414,998 | Anti-HER2 affibody and switchable chimeric antigen receptor using same as switch molecule In force · From the USPTO record | In force | From the USPTO record | |
| US 12,624,099 | Polypeptide Improved in Protein Purity and Affinity for Antigen, Conjugate Thereof with Antibody or Antigen-Binding Fragment, and Preparation Method Therefor In force · High confidence | In force | High confidence |
Also on record, not counted in the 11: 4 patents in force now held by others. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending